On this page

Ketoconazole

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Ketoconazole
Generic name
Ketoconazole
Dosage form
Shampoo, Suspension
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
15
Packages
15
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Ketoconazole 20 mg/mL 197853 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Shampoo, Suspension
Route of administration
Topical
Presentations
30

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Azole Antifungal [EPC] EPC All 44 members
Azoles [CS] CS All 44 members
Cytochrome P450 3A4 Inhibitors [MoA] MoA All 118 members
Cytochrome P450 3A5 Inhibitors [MoA] MoA 7 members — no class page
P-Glycoprotein Inhibitors [MoA] MoA All 105 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
076942
Application type
ANDA · Abbreviated New Drug Application
Approval date
April 11, 2005
Sponsor
COSETTE PHARMS NC
Products on application
1
Submissions recorded
5
Products approved under application 076942.
Product Trade name Form Strength Ingredient Status TE Flags
076942-001 KETOCONAZOLE SHAMPOO KETOCONAZOLE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 076942.
Type No. Action Status Date Review
Supplement 24 Labeling Approved February 18, 2020 Standard
Supplement 20 Labeling Approved August 31, 2015 Standard
Supplement 19 Labeling Approved January 3, 2013 Standard
Supplement 4 Manufacturing (CMC) Approved October 17, 2007 —
Original application 1 Approved April 11, 2005 —

Review documents

  • 0 · Original application · December 6, 2007

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250424). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250424 HUMAN PRESCRIPTION DRUG · 20240315 HUMAN PRESCRIPTION DRUG · 20221101

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Ketoconazole shampoo, 2%, is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare ). Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in normalization of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply the shampoo to the damp skin of the affected area and a wide margin surrounding this area. Lather, leave in place for 5 minutes, and then rinse off with water. One application of the shampoo should be sufficient.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Ketoconazole shampoo, 2%, is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Clinical Trials Experience In 11 double-blind trials in 264 patients using ketoconazole shampoo, 2%, for the treatment of dandruff or seborrheic dermatitis, an increase in normal hair loss and irritation occurred in less than 1% of patients. In three open-label safety trials in which 41 patients shampooed 4-10 times weekly for six months, the following adverse experiences each occurred once: abnormal hair texture, scalp pustules, mild dryness of the skin, and itching. As with other shampoos, oiliness and dryness of hair and scalp have been reported. In a double-blind, placebo-controlled trial in which patients with tinea versicolor were treated with either a single application of ketoconazole shampoo, 2%, (n=106), a daily application for three consecutive days (n=107), or placebo (n=105), drug-related adverse events occurred in 5 (5%), 7 (7%) and 4 (4%) of patients, respectively. The only events that occurred in more than one patient in any one of the three treatment groups were pruritus, application site reaction, and dry skin; none of these events occurred in more than 3% of the patients in any one of the three groups. Post-marketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. The following adverse drug reactions have been identified during post-marketing experience with ketoconazole shampoo, 2%: there have been reports of hair discoloration and abnormal hair texture, itching, skin burning sensation, contact dermatitis, hypersensitivity, angioedema, alopecia, rash, urticaria, skin irritation, dry skin, and application site reactions.

Description

openFDA Drug Labeling

DESCRIPTION Ketoconazole Shampoo, 2% is a red-orange liquid for topical application, containing the broad spectrum synthetic antifungal agent ketoconazole in a concentration of 2% in an aqueous suspension. It also contains: coconut fatty acid diethanolamide, disodium laureth sulfosuccinate, FD & C Red No. 40, hydrochloric acid, imidurea, laurdimonium hydroxypropyl hydrolyzed collagen, PEG-120 methyl glucose dioleate, purified water, sodium chloride, sodium hydroxide, and sodium lauryl ether sulfate. Ketoconazole is cis -1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1 H -imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy] phenyl]piperazine and has the following structural formula: Chemical Structure

OVERDOSAGE Ketoconazole shampoo, 2%, is intended for external use only. In the event of accidental ingestion, supportive and symptomatic measures should be employed. Induced emesis and gastric lavage should not be performed to avoid aspiration.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Ketoconazole Shampoo, 2%, is a red-orange liquid supplied in a 4-fluid ounce nonbreakable plastic bottle (NDC 68788-8868-1). Storage conditions: Store at 20oC to 25oC (68oF to 77oF) [see USP Controlled Room Temperature]. Protect from light. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Rev. 07/2024 8-0592CP1 Relabeled By: Preferred Pharmaceuticals Inc.

Adverse event reports

Source: openFDA FAERS
17,282
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: KETOCONAZOLE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-3288-0 50090-3288 A-S Medication Solutions 118.28 mL in 1 BOTTLE, PLASTIC (50090-3288-0) November 30, 2017
50090-7538-0 50090-7538 A-S Medication Solutions 120 mL in 1 BOTTLE, PLASTIC (50090-7538-0) April 21, 2025
63629-8675-1 63629-8675 Bryant Ranch Prepack 120 mL in 1 BOTTLE (63629-8675-1) February 9, 2022
71335-2839-1 71335-2839 Bryant Ranch Prepack 120 mL in 1 BOTTLE (71335-2839-1) October 24, 2025
72162-1409-2 72162-1409 Bryant Ranch Prepack 120 mL in 1 BOTTLE (72162-1409-2) June 20, 2024
0713-0592-04 0713-0592 Cosette Pharmaceuticals, Inc. 120 mL in 1 BOTTLE, PLASTIC (0713-0592-04) February 7, 2025
72603-878-01 72603-878 Northstar Rx LLC 120 mL in 1 BOTTLE (72603-878-01) December 1, 2025
68071-5294-4 68071-5294 NuCare Pharmaceuticals, Inc. 120 mL in 1 BOTTLE (68071-5294-4) June 2, 2026
68071-3930-4 68071-3930 NuCare Pharmaceuticals,Inc. 120 mL in 1 BOTTLE (68071-3930-4) December 8, 2025
45802-465-64 45802-465 Padagis Israel Pharmaceuticals Ltd 120 mL in 1 BOTTLE (45802-465-64) January 19, 2010
68788-8257-1 68788-8257 Preferred Pharmaceuticals Inc. 120 mL in 1 BOTTLE, PLASTIC (68788-8257-1) September 16, 2022
68788-8868-1 68788-8868 Preferred Pharmaceuticals Inc. 120 mL in 1 BOTTLE, PLASTIC (68788-8868-1) April 24, 2025
71205-105-72 71205-105 Proficient Rx LP 120 mL in 1 BOTTLE, PLASTIC (71205-105-72) September 4, 2018
71713-097-04 71713-097 THIRTY MADISON INC 120 mL in 1 BOTTLE, PLASTIC (71713-097-04) April 11, 2005
63646-010-04 63646-010 TOLMAR Inc. 120 mL in 1 BOTTLE, PLASTIC (63646-010-04) April 11, 2005
50090-3288 50090-3288 A-S Medication Solutions — April 11, 2005
50090-7538 50090-7538 A-S Medication Solutions — February 7, 2025
63629-8675 63629-8675 Bryant Ranch Prepack — January 19, 2010
71335-2839 71335-2839 Bryant Ranch Prepack — January 19, 2010
72162-1409 72162-1409 Bryant Ranch Prepack — January 19, 2010
0713-0592 0713-0592 Cosette Pharmaceuticals, Inc. — February 7, 2025
72603-878 72603-878 Northstar Rx LLC — December 1, 2025
68071-5294 68071-5294 NuCare Pharmaceuticals, Inc. — December 1, 2025
68071-3930 68071-3930 NuCare Pharmaceuticals,Inc. — January 19, 2010
45802-465 45802-465 Padagis Israel Pharmaceuticals Ltd — January 19, 2010
68788-8257 68788-8257 Preferred Pharmaceuticals Inc. — September 16, 2022
68788-8868 68788-8868 Preferred Pharmaceuticals Inc. — April 24, 2025
71205-105 71205-105 Proficient Rx LP — October 1, 2016
71713-097 71713-097 THIRTY MADISON INC — April 11, 2005
63646-010 63646-010 TOLMAR Inc. — April 11, 2005

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.